Allotment results | Simcere Pharmacy-B (02410) 47.88% of IPO subscribers were successfully allotted at a final price of HKD 12.1
Tongyuan Kangyao Pharmaceutical-B (02410) placement ended.
On August 20th, the placement of Tongyuan Kangyao Pharmaceutical-B (02410) ended. The offer price was HK$12.1, and the final price was set at HK$12.1 per share, with each lot costing HK$6050.
For the public offering, there were 974 applicants, with a 47.88% allotment rate for one lot, and a subscription multiple of approximately 2.29 times. The number of international placement applicants was not disclosed, with a subscription multiple of approximately 1.01 times.
The number of international placement applicants was not disclosed, with an oversubscription multiple indicating moderate oversubscription.
Related Articles

Air China Limited (00753) recommends appointing Liu Tiexiang as an executive director.

According to the post-IPO stock option plan of CARSGEN-B (02171), 6.74 million stock options were granted.

Meta (META.US) is negotiating with media organizations on AI content licensing matters.
Air China Limited (00753) recommends appointing Liu Tiexiang as an executive director.

According to the post-IPO stock option plan of CARSGEN-B (02171), 6.74 million stock options were granted.

Meta (META.US) is negotiating with media organizations on AI content licensing matters.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025